drugset / Trial / NCT06356662
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Phase 1
Recruiting
60 enrolled
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Timeline
- Start
- 2024-01-23
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |